What Activity Assays Miss: Detecting Inactive Trypsin Fragments In Final Formulation

Enzyme residues in biopharmaceutical manufacturing present a persistent safety challenge that conventional activity-based testing cannot fully address. Inactivated enzyme proteins and fragments remain immunogenic even when they no longer exhibit catalytic function, creating blind spots in traditional quality control processes. ELISA-based detection offers an alternative approach by identifying protein presence independent of enzymatic activity, enabling manufacturers to detect both active and inactive trypsin throughout production workflows.

High-sensitivity polyclonal antibodies can identify trypsin concentrations as low as 0.5 ng/ml across diverse sample matrices, from in-process materials to final drug products. The testing methodology delivers results in approximately two to 2.5 hours while maintaining precision levels below 4% and accuracy within 10% of gravimetric standards. This activity-independent detection strategy addresses a critical gap in process analytical technology for cell culture and bioprocessing applications where enzymatic treatments are standard practice. Access the complete technical specifications and performance data to evaluate implementation requirements for your manufacturing quality systems.